bci

BCI ((E)-BCI) is an allosteric inhibitor of dual-specificity phosphatase (DUSP; EC50s: 13.3 and 8.0 μM for DUSP6 and DUSP1 in cells) and does not inhibit DUSP5.

(E Z)-BCI (NSC-150117), a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory properties, reduces LPS-induced inflammatory mediators and ROS production in macrophage cells by activating the Nrf2 signaling axis and inhibiting the NF-κB pathway.

BCI-215 causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling

BCI hydrochloride specifically inhibits DUSP6 and DUSP1 with EC50s of 13.3 and 8.0 μM in cells, respectively. BCI hydrochloride does not inhibit DUSP5. BCI hydrochloride is an allosteric inhibitor of dual specificity phosphatase (DUSP).

BCI-121 is a substrate-competitive SMYD3 inhibitor that inhibits the proliferation of the cancer cell.

BCI-137 is an Argonaute 2 ligand. It acts by targeting the MicroRNA binding domain.

MGS-0039 is a group II metabotropic glutamate receptor (mgluR2/3) antagonist. Antidepressant-like action of group II mGlu receptor antagonists does not depend on serotonergic system activation. However, the AMPA receptor seems to play a key role in the an

Sabcomeline is a selective M1 receptor partial agonist.

Abciximab (C7E3) is a mouse human chimeric monoclonal antibody that is a potent glycoprotein IIb IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb IIIa, vitronectin and Mac-1 receptors.

DCBCI0901 is an inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity.

Bismuth Subcitrate Potassium is an antibiotic that acts against 12 species of Helicobacter pylori, inhibits the histamine H2 receptor, and can be used to study diarrhea and peptic ulcer disease in vulnerable patients with SARS-CoV-2 infections.